Compare iShares 10 20 Year Treasury Bond ETF (TLH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 10 20 Year Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $92.19 (market cap $11.02B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: iShares 10 20 Year Treasury Bond ETF and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 10 20 Year Treasury Bond ETF for 60 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TLH | XBI | |
|---|---|---|
Market Cap | $11.02B | $10.11B |
Volume | 6,609,157 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $105.36 | $169.55 |
52-Week Low | $91.34 | $104.99 |
Typical Hold Time | 60 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLH (iShares 10-20 Year Treasury Bond ETF) trades at $92.11, up 0.72% with bearish technical signals from moving averages. The ETF shows unusually high trading volume, up 66% recently, amid a challenging bond market environment where 10-year Treasury yields have reached multi-decade highs. Recent dividend payments of $0.36-$0.38 reflect the fund's income-generating nature.
Outlook remains cautious as rising bond yields pressure long-term Treasury ETFs. Investment opportunity exists for income-focused investors seeking regular dividends, but risks include continued yield increases and Federal Reserve policy uncertainty. The bearish technical picture suggests near-term pressure on bond ETF valuations.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
